{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:37:22Z","timestamp":1782135442390,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,4]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n \n This study assessed real\u2010world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (\n INSTI<\/jats:styled-content>\n ), and reverse transcriptase inhibitor (\n RTI<\/jats:styled-content>\n ), among suppressed people living with\n HIV<\/jats:styled-content>\n in Europe.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This observational cohort enrolled adults with\n HIV<\/jats:styled-content>\n from 28 sites across Europe who were switching to a two\u2010drug regimen of an\n INSTI<\/jats:styled-content>\n plus a nucleoside reverse transcriptase inhibitor or non\u2010nucleoside reverse transcriptase inhibitor while suppressed [viral load (\n VL<\/jats:styled-content>\n ) <50 copies\/\n mL<\/jats:styled-content>\n ]. Participants were followed from regimen start date (baseline) until the earliest of 96\u2009weeks, regimen discontinuation, loss to follow\u2010up, or death. The primary endpoints were suppression, low\u2010level viraemia (\n VL<\/jats:styled-content>\n \u226550 to <200 copies\/\n mL<\/jats:styled-content>\n ), and high\u2010level viraemia (\n VL<\/jats:styled-content>\n \u2265200 copies\/\n mL<\/jats:styled-content>\n ) at 24\u2010, 48\u2010 and 96\u2010weeks post\u2010baseline, and virologic failure (\n VF<\/jats:styled-content>\n ) within 96\u2009weeks (2 consecutive\n VLs<\/jats:styled-content>\n \u226550 copies\/\n mL<\/jats:styled-content>\n or 1\n VL<\/jats:styled-content>\n \u226550 copies\/\n mL<\/jats:styled-content>\n followed by regimen discontinuation). Adverse events and discontinuations were also described.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n 737 individuals switched to DTG\u2009+\u20093TC (536, 72.7%), DTG\u2009+\u2009RPV (186, 25.2%) and other INSTI+RTI regimens (15, 2.0%). At 24\u2010,48\u2010, and 96\u2009weeks of follow up, >98% of individuals with VL data maintained suppression; among VLs \u226550 copies\/mL, most (19\/23; 82.6%) were low\u2010level viraemia. Five individuals (<1%, DTG\u2009+\u20093TC:2; DTG\u2009+\u2009RPV:3) experienced VF. Forty\u2010seven non\u2010serious drug\u2010related AEs were reported by 38 participants (5.4%); 2 people experienced serious AEs (0.3%). Regimen discontinuations were infrequent (\n n<\/jats:italic>\n \u2009=\u200939, 5.3%) and most commonly attributed to tolerability issues (\n n<\/jats:italic>\n \u2009=\u200917).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Among suppressed people living with\n HIV<\/jats:styled-content>\n in a real\u2010world setting,\n INSTI<\/jats:styled-content>\n +\n RTI<\/jats:styled-content>\n two\u2010drug regimens were highly effective and well tolerated over 96\u2009weeks of follow\u2010up.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/hiv.70187","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:21:29Z","timestamp":1767792089000},"page":"572-584","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of two\u2010drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with\n HIV<\/scp>\n : Data from the\n COMBINE<\/scp>\n \u20102 study"],"prefix":"10.1111","volume":"27","author":[{"given":"Cristina","family":"Mussini","sequence":"first","affiliation":[{"name":"University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Henegar","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique Paris France"},{"name":"The European treatment network for HIV, hepatitis and global infectious diseases (NEAT ID) Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"de Wit","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Saint Pierre Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Johnson","sequence":"additional","affiliation":[{"name":"Royal Free Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-9100","authenticated-orcid":false,"given":"Eugenia","family":"Quiros\u2010Roldan","sequence":"additional","affiliation":[{"name":"University of Brescia and ASST Spedali Civili di Brescia Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kenyon","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Deschanvres","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Nantes H\u00f4tel DIEU Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zucman","sequence":"additional","affiliation":[{"name":"H\u00f4pital Foch Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2844-1612","authenticated-orcid":false,"given":"Frank","family":"Post","sequence":"additional","affiliation":[{"name":"Kings College NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Movahedi","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Comi","sequence":"additional","affiliation":[{"name":"ASST Papa Giovanni XXIII Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust London UK"},{"name":"King's College London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liegeon","sequence":"additional","affiliation":[{"name":"Saint Louis and Lariboisi\u00e8re Hospitals Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Martin","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Saint Pierre Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Edwards","sequence":"additional","affiliation":[{"name":"Royal Free Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Tiecco","sequence":"additional","affiliation":[{"name":"University of Brescia and ASST Spedali Civili di Brescia Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Delforge","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Saint Pierre Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Ragone","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aboud","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Research Organization (KC) Ltd London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[{"name":"The European treatment network for HIV, hepatitis and global infectious diseases (NEAT ID) Brussels Belgium"},{"name":"Chelsea and Westminster Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-9689","authenticated-orcid":false,"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350901400109"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0093-9"},{"key":"e_1_2_10_4_1","unstructured":"European AIDS Clinical Society.EACS Guidelines version 12.1. 2024. EACS Guidelines 2024 \u2014 EACS Guidelines.2024."},{"key":"e_1_2_10_5_1","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.2024https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_2_10_10_1","unstructured":"PunekarYS ParksD JoshiM et al.Effectiveness and Safety of Dolutegravir Two\u2010Drug Regimens in Virologically Suppressed People Living with HIV: A Systematic Literature Review and Meta\u2010Analysis of Real\u2010World Evidence."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00522-7"},{"key":"e_1_2_10_12_1","unstructured":"GagliardiniR LorenziniP Cozzi\u2010LepriA et al.Effect of past virological failure on dolutegravir lamivudine as a maintenance regimen. In: Paper presented at: Conference on retroviruses and opportunistic infections; 2020 March 8\u201311; Boston MA United States."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.09.002"},{"key":"e_1_2_10_14_1","unstructured":"MaggioloF ComiL GulminettiR et al.Dolutegravir + lamivudine in patients with suppressed HIV\u2010RNA: long term virologic and immunologic results of a multicenter cohort. In: Paper presented at: HIV Drug Therapy Glasgow 2018; 2018 October 28\u201331; Glasgow UK."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105893"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016813"},{"key":"e_1_2_10_17_1","unstructured":"FraysseJ PriestJ TurnerM et al.Real\u2010world effectiveness and tolerability of dolutegravir and lamivudine 2\u2010drug regimen in people living with HIV: systematic literature review and meta\u2010analysis."},{"key":"e_1_2_10_18_1","unstructured":"SchneiderS BlickG BurkeC et al.Two\u2010Drug Regimens Dolutegravir\/Lamivudine and Dolutegravir\/Ripivirine Are Effective with Few Discontinuations in US Real\u2010World Settings: Results from the TANDEM Study."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002942"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001125"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(16)30002-0"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054788"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00210-8"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-08749-8"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.000000000000348"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa195"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/20503121241260613"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa177"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2965325"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873408"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13467"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae560"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15040936"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0024-z"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:10:06Z","timestamp":1775452206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/hiv.70187"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70187","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}